24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial

Qingxian Cai, Xiaohong Zhang, Chaoshuang Lin, Xiaoqiong Shao, Yujuan Guan, Hong Deng, Min Wei, Mingshou Huang, Zefang Ren, Ling Lu, Yongyu Mei, Min Xu, Jianyun Zhu, Haiyan Shi, Guoli Lin, Ying Liu, Fengyu Hu, Qiumin Luo, Yun Lan, Fengxia Guo, Zhixin Zhao and Zhiliang Gao

PLOS ONE, 2015, vol. 10, issue 10, 1-14

Abstract: Objectives: The optimal treatment of hepatitis C virus (HCV) genotype 6 is unclear owing to its limited geographic distribution. Because of a high predictive value of rapid virological response (RVR) for sustained virological response (SVR), we conducted an open-label randomized controlled trial to compare 24- and 48-week peginterferon/ribavirin combination therapy for patients with HCV genotype 6 in Southern China who achieved an RVR. Methods and Findings: Treatment-naive, non-cirrhotic patients with chronic hepatitis C genotype 6 were treated with pegylated interferon α-2a (180 μg/week) and ribavirin (800–1,200 mg, according to weight) for 4 weeks. Patients who achieved an RVR, which was defined as HCV RNA negativity at week 4 (

Date: 2015
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140853 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 40853&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0140853

DOI: 10.1371/journal.pone.0140853

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().